Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis.
The Authors have studied the effects of somatostatin (SRIF) treatment in an infant affected by hypoglycemia due to nesidioblastosis. During iv infusion with SRIF we observed a marked increase of blood glucose levels; concomitantly insulin secretion was almost completely suppressed. In contrast, during treatment with protamine zinc-somatostatin (PZ-SRIF), a long acting SRIF preparation, the blood glucose levels did not rise and insulin concentrations were inappropriately elevated. Therefore in this case the long term treatment of hypoglycemia due to nesidioblastosis with PZ-somatostatin was unfeasible.
D007516:Adenoma, Islet Cell / Q000150:complications*; D001786:Blood Glucose / Q000378:metabolism; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D007328:Insulin / Q000097:blood; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000150:complications*; D011479:Protamines / Q000627:therapeutic use*; D013004:Somatostatin / Q000627:therapeutic use*
D001786:Blood Glucose; D004338:Drug Combinations; D007328:Insulin; D011479:Protamines; C029997:somatostatin, protamine zinc-; D013004:Somatostatin; D013006:Growth Hormone